{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Reference+product&page=8",
    "query": {
      "intervention": "Reference product",
      "page": 8
    },
    "page_size": 10
  },
  "pagination": {
    "page": 8,
    "page_size": 10,
    "total_count": 362,
    "total_pages": 37,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Reference+product&page=9&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Reference+product&page=7&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-31T11:09:18.111Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04921371",
      "title": "Six Week Study of Experimental Mouth Rinses: Effect on Gingivitis and Plaque",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Gingivitis",
        "Plaque"
      ],
      "interventions": [
        {
          "name": "Colgate® Cavity Protection Toothpaste",
          "type": "OTHER"
        },
        {
          "name": "Listerine® Cool Mint®",
          "type": "OTHER"
        },
        {
          "name": "Concept Curve Winter Series Toothbrush",
          "type": "OTHER"
        },
        {
          "name": "5% Hydroalcohol Mouthrinse",
          "type": "OTHER"
        },
        {
          "name": "Mouthrinse Prototype 1",
          "type": "OTHER"
        },
        {
          "name": "Mouthrinse Prototype 2",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Johnson & Johnson Consumer Inc. (J&JCI)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 157,
      "start_date": "2019-10-08",
      "completion_date": "2019-12-19",
      "has_results": false,
      "last_update_posted_date": "2023-09-28",
      "last_synced_at": "2026-10-31T11:09:18.111Z",
      "location_count": 1,
      "location_summary": "Fort Wayne, Indiana",
      "locations": [
        {
          "city": "Fort Wayne",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04921371"
    },
    {
      "nct_id": "NCT01260948",
      "title": "10 mg Donepezil Hydrochloride Orally Disintegrating Tablets Under Non-Fasting Conditions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Donepezil Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Aricept®",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Teva Pharmaceuticals USA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2006-04",
      "completion_date": "2006-05",
      "has_results": true,
      "last_update_posted_date": "2011-02-21",
      "last_synced_at": "2026-10-31T11:09:18.111Z",
      "location_count": 1,
      "location_summary": "East Grand Forks, Minnesota",
      "locations": [
        {
          "city": "East Grand Forks",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01260948"
    },
    {
      "nct_id": "NCT01260922",
      "title": "10 mg Donepezil Hydrochloride Orally Disintegrating Tablets Under Fasting Conditions.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Donepezil Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Aricept®",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Teva Pharmaceuticals USA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2006-04",
      "completion_date": "2006-05",
      "has_results": true,
      "last_update_posted_date": "2011-02-21",
      "last_synced_at": "2026-10-31T11:09:18.111Z",
      "location_count": 1,
      "location_summary": "East Grand Forks, Minnesota",
      "locations": [
        {
          "city": "East Grand Forks",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01260922"
    },
    {
      "nct_id": "NCT00829673",
      "title": "Dexmethylphenidate Hydrochloride Tablets Under Non-Fasting Conditions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Dexmethylphenidate Hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Teva Pharmaceuticals USA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2004-06",
      "completion_date": "2004-06",
      "has_results": true,
      "last_update_posted_date": "2024-08-19",
      "last_synced_at": "2026-10-31T11:09:18.111Z",
      "location_count": 1,
      "location_summary": "Saint Charles, Missouri",
      "locations": [
        {
          "city": "Saint Charles",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00829673"
    },
    {
      "nct_id": "NCT06265272",
      "title": "Value of [68Ga]Ga-PSMA-11 PET/MRI in the Assessment of Liver Cirrhosis",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Liver Cirrhosis",
        "Hepatic Cell Carcinoma",
        "Portal Hypertension"
      ],
      "interventions": [
        {
          "name": "Injection of a gadolinium contrast agen",
          "type": "DRUG"
        },
        {
          "name": "Radiotracer Injection",
          "type": "DRUG"
        },
        {
          "name": "Imaging",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 45,
      "start_date": "2023-12-10",
      "completion_date": "2028-12-19",
      "has_results": false,
      "last_update_posted_date": "2026-10-14",
      "last_synced_at": "2026-10-31T11:09:18.111Z",
      "location_count": 1,
      "location_summary": "Charlestown, Massachusetts",
      "locations": [
        {
          "city": "Charlestown",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06265272"
    },
    {
      "nct_id": "NCT02685137",
      "title": "Efficacy and Safety of Stannsoporfin in Neonates",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Nutritional and Metabolic Diseases"
      ],
      "interventions": [
        {
          "name": "stannsoporfin",
          "type": "DRUG"
        },
        {
          "name": "Sham Injection",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Hours",
        "maximum_age": "36 Hours",
        "sex": "ALL",
        "summary": "12 Hours to 36 Hours"
      },
      "enrollment_count": 185,
      "start_date": "2002-05-01",
      "completion_date": "2013-02",
      "has_results": false,
      "last_update_posted_date": "2019-10-29",
      "last_synced_at": "2026-10-31T11:09:18.111Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02685137"
    },
    {
      "nct_id": "NCT00944177",
      "title": "Study to Evaluate the Bioequivalence of a Test Tablet Formulation of Metformin HCl (1000 mg), Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (Glucophage®, Bristol-Myers Squibb Company) in Fasted, Healthy, Adult Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Metformin HCl",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Torrent Pharmaceuticals Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2009-07-23",
      "last_synced_at": "2026-10-31T11:09:18.111Z",
      "location_count": 1,
      "location_summary": "Saint Charles, Missouri",
      "locations": [
        {
          "city": "Saint Charles",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00944177"
    },
    {
      "nct_id": "NCT02984852",
      "title": "Study to Evaluate the Relative Bioavailability of Fixed-dose Combination Tablet Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) as a Whole Tablet, as a Split Tablet, and as Crushed Tablet in Healthy Adult Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Darunavir (DRV)",
          "type": "DRUG"
        },
        {
          "name": "Cobicistat (COBI)",
          "type": "DRUG"
        },
        {
          "name": "Emtricitabine (FTC)",
          "type": "DRUG"
        },
        {
          "name": "Tenofovir Alafenamide (TAF)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Scientific Affairs, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 30,
      "start_date": "2016-12",
      "completion_date": "2017-02",
      "has_results": false,
      "last_update_posted_date": "2025-02-03",
      "last_synced_at": "2026-10-31T11:09:18.111Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02984852"
    },
    {
      "nct_id": "NCT07049055",
      "title": "A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Cancer, Metastatic",
        "PDAC - Pancreatic Ductal Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "E-EDV-D682",
          "type": "DRUG"
        },
        {
          "name": "EDV-GC",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Nab paclitaxel.",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Engeneic Pty Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 144,
      "start_date": "2026-01-12",
      "completion_date": "2028-09",
      "has_results": false,
      "last_update_posted_date": "2026-02-27",
      "last_synced_at": "2026-10-31T11:09:18.111Z",
      "location_count": 4,
      "location_summary": "El Segundo, California • Summit, New Jersey • New York, New York + 1 more",
      "locations": [
        {
          "city": "El Segundo",
          "state": "California"
        },
        {
          "city": "Summit",
          "state": "New Jersey"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Maumee",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07049055"
    },
    {
      "nct_id": "NCT02727205",
      "title": "Irritation and Sensitization Potential of Repeat Applications of Rotigotine Patch",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Bioequivalence - Irritation and Sensitization Potential of Transdermal Patch"
      ],
      "interventions": [
        {
          "name": "Rotigotine Transdermal System",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Inflamax Research Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 260,
      "start_date": "2013-08",
      "completion_date": "2013-10",
      "has_results": false,
      "last_update_posted_date": "2016-04-04",
      "last_synced_at": "2026-10-31T11:09:18.111Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02727205"
    }
  ]
}